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Abstract
Murid c-herpesvirus-4 (MuHV-4) promotes polyclonal B cell activation and establishes latency in memory B cells via unclear
mechanisms. We aimed at exploring whether B cell receptor specificity plays a role in B cell susceptibility to viral latency and
how this is related to B cell activation. We first observed that MuHV-4-specific B cells represent a minority of the latent
population, and to better understand the influence of the virus on non-MuHV-4 specific B cells we used the SWHEL mouse
model, which produce hen egg lysozyme (HEL)-specific B cells. By tracking HEL+ and HEL2 B cells, we showed that in vivo
latency was restricted to HEL2 B cells while the two populations were equally sensitive to the virus in vitro. Moreover,
MuHV-4 induced two waves of B cell activation. While the first wave was characterized by a general B cell activation, as
shown by HEL+ and HEL2 B cells expansion and upregulation of CD69 expression, the second wave was restricted to the
HEL2 population, which acquired germinal center (GC) and plasma cell phenotypes. Antigenic stimulation of HEL+ B cells led
to the development of HEL+ GC B cells where latent infection remained undetectable, indicating that MuHV-4 does not
benefit from acute B cell responses to establish latency in non-virus specific B cells but relies on other mechanisms of the
humoral response. These data support a model in which the establishment of latency in B cells by c-herpesviruses is not
stochastic in terms of BCR specificity and is tightly linked to the formation of GCs.
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Introduction
The murid c-herpesvirus-4 (MuHV-4, also known as MHV-68
or cHV-68) has led to valuable insights in understanding human c-
herpesvirus related diseases caused by Epstein-Barr virus (EBV)
and Kaposi’s sarcoma associated herpesvirus (KSHV) [1].
Whereas primo infection by c-herpesviruses can be responsible
for lymphoproliferative disorders in immune competent hosts, they
are usually well controlled [2]. As with EBV, MuHV-4 is mainly
lymphotropic and establishes latency in class-switched and
germinal center (GC) B cells [3,4]. The course of the infection
in mice is now well described (see [5] and [1]). Upon intranasal
inoculation, infection starts with an acute lung infection controlled
by the CD8+ T cell response. The virus then disseminates to
secondary lymph organs via serial events of lymphoid/myeloid
cellular exchanges [6] where it promotes a CD4-dependent
polyclonal B cell response and finally establishes latency in long-
lived memory B cells [1,5,7,8]. This polyclonal B cell activation
can lead to the emergence of auto-antibodies but MuHV-4
infection is usually not associated with the development of auto-
immune diseases or lymphomas in immune competent mice [9].
CD4+ T cells, and in particular follicular helper T cells [10], have
been shown to be essential for the establishment of MuHV-4
latency. Antibody-mediated depletion experiments [11,12] as well
as work performed on MHC class II deficient mice [13] (which are
CD4+ T cells deficient) have led to similar observations, that the
absence of CD4+ T cells leads to lower latency levels.
On the virus side, few proteins have been shown to be involved
in the establishment of latency [1]. Among them, M2 has received
particular interest for its ability to interfere with B cell activation.
Studies performed with M2-deficient MuHV-4 have shown its
essential role in the establishment of latency, although it is not
required for acute lung infection [14,15]. Biochemical analysis
have established that M2 is able to interact with the Fyn/Vav,
Plcc2 and PI3K pathways, involved in BCR signaling [16–18]. In
vivo, B cells infected by M2-deficient MuHV-4 have been shown
to acquire a GC phenotype comparable with the WT virus, but
were unable to class-switch and differentiate into plasma cells [19].
MuHV-4 LANA has recently been shown to stabilize cellular Myc
and promotes its activity, leading to B cell proliferation, a process
required for GC formation and viral latency [20].
The lower level of viral latency observed in mice deprived of
CD4+ T cells as well as with M2-deficient MuHV-4 are good
examples showing that the establishment of MuHV-4 latency relies
on mechanisms that mix the physiologic B cell response and the
intervention of viral modulators. Several questions remain to be
explored to better understand this complex interaction: How does
MuHV-4 trigger a polyclonal B cell activation? Are latently
infected B cells also polyclonal, or is latency restricted to MuHV-4
specific B cells? Finally, what are the respective roles for the virus
and the B cells in the establishment of latency?
Until recently, those were difficult questions to address
experimentally because of two major hurdles on the virus and
the B cell sides. At peak of latency (,14 days post-infection in
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C57BL/6 mice), latently infected B cells represent a low
percentage of total B cells [3,4] and tracking these cells was
impossible until the development of a YFP expressing MuHV-4
[4]. On the B cell side, questions concerning BCR specificity are
delicate to address due to the enormous diversity of the B cell
repertoire and to the difficulty to trace one clonal population, but
major improvement was made with the development of the switch
hen egg lysozyme mice (SWHEL) [21–24]. Based on the MD4
model [25], SWHEL mice have been engineered to contain up to
,10% of HEL-specific B cells. But contrary to MD4 mice, SWHEL
HEL+ B cells can perform GC reactions in a competitive
environment, class-switch and differentiate in long-lived memory
B cells. Moreover, HEL-specific (HEL+) and non-specific (HEL2)
populations can easily be distinguished by direct staining of the
BCR with fluorescently labeled HEL.
In the present study, we aimed at clarifying the role of BCR
specificity in the establishment of MuHV-4 latency in B cells.
Taking advantage of the SWHEL mice and the YFP-MuHV-4 we
designed experiments to study in parallel how MuHV-4 influences
a normal B cell repertoire (HEL2) and a clonal population of non-
virus specific B cells (HEL+) in order to determine in which
population latency is established and how this relates with B cell
activation.
Results
MuHV-4 latency is not restricted to virus-specific B cells
To evaluate the frequency of MuHV-4 specific B cells in
infected and non-infected populations, we challenged C57BL/6
mice with YFP-MuHV-4. Infected and non-infected CD19+ B
cells were sorted at 14 dpi based on their YFP expression and used
in an ELISPOT assay to evaluate the number of total IgGs and
anti-MuHV-4 IgGs secreting cells (Figure 1A). Both YFP2 and
YFP+ B cells showed a low frequency of virus-specific antibody-
secreting cells (ASC) cells when compared to the total ASC. That
is, ,10% of total ASC for the YFP2, and ,1% for the YFP+
populations, showing that in both populations the majority of ASC
are not MuHV-4 specific. As the frequency of GC B cells (GL-7+,
CD95+) is significantly different between YFP+ and YFP2 B cells
(Figure 1B), we tried to refine our analysis by sorting infected and
non-infected GC cells based on GL-7 and CD95 expression. Yet,
purified cells died quickly and could not be used for ELISPOT
assays, probably due to anti-CD95 induced apoptosis [26]. Our
ELISPOT assay did not include the monitoring of IgGs specific for
non-structural proteins. However, it would be unlikely if they
accounted for the 90 to 99% of the ASC not detected in our anti-
MuHV-4 IgGs assay. These data indicate that latent infection is
not restricted to MuHV-4 specific B cells and that the virus is able
to promote the activation of non-virus-specific B cells indepen-
dently of their infection status. In order to explore these two
points, we next used the SWHEL mice [21], which allowed us to
monitor MuHV-4 influence on non-virus-specific HEL+ B cells.
HEL+ B cells are not latently infected by MuHV-4
SWHEL mice were infected with YFP-MuHV-4 and we
monitored YFP expression in HEL+ and HEL2 B cells 14 dpi
(Figure 2A). While we did not detect YFP expression in the HEL+
population, HEL2 B cells harbored a frequency of YFP+ cells
comparable with what has been previously reported in WT B cells
[4]. We confirmed that HEL2 B cells are solely latently infected by
sorting HEL+ and HEL2 B cells on which we monitored
reactivation of latent virus by ex vivo explant co-culture assay
(Figure 2B) and the presence of viral DNA by limiting dilution
PCR (Figure 2C). It is important to note that HEL2 B cells emerge
from a spontaneous replacement of the Vh10 exon encoding for
the HEL-specific heavy chain leading to the reconstitution of a
polyclonal repertoire [21], minimizing the impact of genetic
differences between these two populations. However, HEL+ B cells
only belong to the B-2 lineage, while HEL2 differentiate into both
B-1 and B-2 B cells [21]. It is unknown in which population of B
cells MuHV-4 latency is established. To evaluate if the B-2 bias of
the HEL+ B cells would account for their resistance to latent
infection, we phenotyped latently infected cells in C57BL/6 mice
(Figure S1). B-2 B cells represented the vast majority of YFP+ B
cells, but a small fraction of latently infected cells was also detected
in B-1a and B-1b B cells. The proportion of B-2, B-1a and B-1b in
YFP+ and YFP2 B cells corresponded to what has been described
for naı̈ve animals, with the B-2 lineage being dominant in splenic
B cells [27]. Overall, these data make it unlikely that the B-2
commitment of HEL+ B cells would explain their resistance to
MuHV-4 latency.
Finally, to monitor that MuHV-4 latency in SWHEL HEL
2 B
cells reproduces what has been described in a normal repertoire,
we determined the phenotype of YFP+ HEL2 B cells (Figure 3). As
for WT B cells (Figure 1B), ,75% of YFP+ HEL2 B cells harbored
a GL-7+ CD95+ phenotype, with a minor fraction harboring a
plasma cell phenotype and ongoing class-switch (CD138+ IgM2).
Together these data show that HEL+ B cells are not latently
infected by MuHV-4 while latency takes place normally in HEL2
B cells.
HEL+ and HEL2 B cells are both sensitive to MuHV-4
infection in vitro
MuHV-4 poorly infects B cells in vitro [28], but work by
Frederico et al overcame this hurdle by developing an in vitro co-
culture assay, and showed that MuHV-4 transits by myeloid cells
in order to get access to B cells [29]. Taking advantage of this
experimental setting we investigated whether the absence of
latently infected HEL+ B cells in vivo was due to an intrinsic
resistance of these cells to the virus. As the YFP-MuHV-4 used for
in vivo experiments allows the detection of latently infected cells
we used in this experiment an EF1a-eGFP+ MuHV-4, in which
GFP expression can be detected 48 h post infection. We used in
Author Summary
Murid c-herpesvirus-4 (MuHV-4) is a good model to study
infectious mononucleosis in mice, in which the virus
ultimately establishes life-long latency in B cells. Whereas
several viral proteins have been shown to modulate B cell
behavior, in the present study we aimed at clarifying the
parameters that dictate the establishment of viral latency
from the B cell perspective. Indeed, the B cell repertoire is
highly diverse and it remains unknown whether latency
takes place randomly in B cells. To study this question, we
isolated latently infected B cells in which we observed a
low frequency of virus-specific B cells, suggesting that viral
latency is not restricted to this population. To better
understand MuHV-4 influence on non-virus specific B cells,
we then followed the fate of B cells specific for a foreign
antigen, hen egg lysozyme (HEL). While in vitro experi-
ments showed that HEL-specific B cells could be acutely
infected by MuHV-4, these cells were resistant to MuHV-4
latent infection in vivo. These results suggest that while
establishment of c-herpesvirus latency is not restricted to
virus-specific B cells, it does not take place randomly in B
cells and relies on mechanisms that remain to be
identified.
MuHV-4 Latency Is Not a Stochastic Event
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parallel gp150+ and a gp1502 viruses, the later leading to a better
B cell infection in co-culture assay [29].
We co-cultured freshly isolated SWHEL splenocytes with
infected RAW-264 or BHK-21 cells, or exposed the splenocytes
to free viruses (Figure 4). 48 h post co-culture, cells were harvested
and GFP expression was monitored in both HEL+ and HEL2 B
cells. Contrasting with our in vivo observations, we observed that
both populations were equally sensitive to MuHV-4 infection
when co-cultured with infected RAW-264, while they remained
not infected with exposed to free virions or co-cultured with
infected BHK-21 (Figure 4). Fitting with previous observations,
percentages of infection were greater with a gp150-deficient virus.
Overall, these in vitro data show that the absence of latently
infected HEL+ B cells in vivo is not due to an intrinsic resistance of
these cells to the virus.
MuHV-4 induces transient B cell activation, but HEL+ B
cells are excluded from late phases of the humoral
response
MuHV-4 is known to induce proliferation of both T cells and B
cells [30]. To evaluate the influence of MuHV-4 on early B cell
activation, we performed a kinetic analysis monitoring the number
and CD69 expression of HEL+ and HEL2 B cells isolated from
spleen and cervical lymph nodes (CLN) (Figure 5). We observed an
increased number of both HEL+ and HEL2 B cells in the spleen
and CLN, which peaked at 14 dpi (Figure 5A), suggesting that
MuHV-4-driven B cell proliferation does not rely on the infection
status. We monitored CD69 expression by two complementary
methods: measuring the intensity of CD69 expression (Figure 5B)
and by evaluating the percentage of CD69high cells (Figure 5C). In
the spleen, beside a small population of CD69high cells observed on
HEL2 B cells at 7 and 14 dpi (Figure 5C), we did not detect a
significant increase of CD69 expression on HEL+ and HEL2 B
cells. On the opposite, in the CLN we observed a peak of CD69
expression on both HEL+ and HEL2 B cells at 7 dpi, which
disappeared at 14 dpi. In both organs, YFP+ B cells were restricted
to the HEL2 B cells indicating that this transient activation of
HEL+ B cells is not sufficient to allow viral latency (Figure S2).
As MuHV-4 is known to establish latency in GC B cells, we next
monitored the late phase of the B cell response by following the
frequency of GC and plasma cells in HEL+ and HEL2 B cells
(Figure 6A & 6B). Although our ELISPOT (Figure 1), proliferation
(Figure 5A) and early activation (Figure 5B & 5C) data suggested a
polyclonal B cell activation upon MuHV-4 infection, HEL+ B cells
did not acquire a GC or plasma cells phenotype at 14 dpi
(Figure 6A). In contrast, HEL2 B cells entered GC reactions and
differentiated into plasma cells (Figure 6B). The frequency of YFP+
cells in HEL2 GC was ,8%, in accordance to what we observed
in C57BL/6 mice (Figure 6C).
Spatial organization of the GC is an essential component of the
B cell response as it dictates the interaction between B cells and the
other cellular players such as follicular helper T cells and dendritic
cells [31]. To have an insight into the organization of the HEL+
and HEL2 B cells in infected mice, we performed immunofluo-
rescent staining on spleen sections from naı̈ve and 14 dpi SWHEL
mice (Figure 7). As natural YFP signal was lost during fixation,
infected cells were revealed with an Alexa-488 anti-GFP antibody.
In naı̈ve mice (Figure 7A), HEL+ B cells were homogeneously
spread in the B cell area of the follicle, and no GFP+ or GC cells
were observed. At 14 dpi, clusters of GL-7+ cells were present in
the B cell area (Figure 7B), in which latently infected cells were
found but HEL+ B cells were excluded. The number of GFP+ cells
Figure 1. MuHV-4 specific B cells represent a minor part of infected and non-infected cells. (A) As presented in the FACS plot, infected
(CD19+ YFP+, black bars) and non-infected (CD19+ YFP2, grey bars) B cells were sorted from C57BL/6 mice 14 dpi. Cells were used to assess the
frequency of total (left) and MuHV-4 specific (right) antibody-secreting cells (ASC) by ELISPOT. These data are from 3 independent experiments, in
each experiment spleens from 3 to 4 mice where pooled before performing the sorts. Post-sorts purities were systematically .95% for YFP+ B cells
and .98% for YFP2 B cells. (B) To monitor the frequency of GC cells in YFP2 and YFP+ B cells, spleens from YFP-MuHV-4 infected C57BL/6 mice (n = 9)
were isolated at 14 dpi for FACS analysis. All the mice harbored a frequency of infected B cells .0,05%, with at least 500 events in the YFP+ gate. A
representative FACS plot showing the frequency of CD95+ GL-7+ cells is shown on top and compiled data obtained from 4 independent experiments
is shown below. Bars represent the average percentage.
doi:10.1371/journal.ppat.1004269.g001
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varied greatly between GCs; a heterogeneity also seen in C57BL/6
mice [32]. However, no matter the number of GFP+ cells present,
we systematically observed an exclusion of the HEL+ B cells from
the GC (Figure 7B).
These histological data confirm our phenotypical analysis
(Figure 6) and overall these data show that while HEL+ B cells
are sensitive to MuHV-4 infection in vitro (Figure 4) and get
activated in vivo (Figure 5), they do not support latent infection
and do not participate to the GC reaction induced by MuHV-4.
SWHEL mice develop an anti-MuHV-4 IgG response but
fail to secrete long-lasting anti-HEL IgGs
To support our phenotypic and histologic observations, PBS or
MuHV-4 challenged SWHEL mice were bled to measure plasmatic
levels of anti-MuHV4 and anti-HEL IgG1, IgG2a and IgG2b
(Figure 8). We were not able to quantify the amount of circulating
antibodies as no standards were available, but the magnitude of
these responses was assessed by systematically analyzing the time
points from identical mice together, limiting the impact of
technical variations. MuHV-4 has been previously shown to
trigger an anti-viral response dominated by the production IgG2a
and IgG2b [8] and our kinetic analysis followed the same pattern
(Figure 8, left graphic). This response appeared between 7 and
14 dpi and gradually increased. For the anti-HEL response,
although we did not detect a HEL+ GC response, we observed a
peak of anti-HEL IgG2a and IgG2b antibodies 14 dpi, which
declined quickly thereafter (Figure 8, right graphic). Naı̈ve SWHEL
mice have a basal level anti-HEL IgGs [21] and the expansion and
transient activation of HEL+ B cells observed in the CLN after
MuHV-4 infection (Figure 5) could account for this burst of anti-
HEL IgGs. However, the fact that this anti-HEL response is
transient indicates the absence of a long-term anti-HEL response,
fitting with our previous observations.
MuHV-4 does not benefit from acute B cell responses to
establish latency in non-virus-specific B cells
Our data show that HEL+ B cells are not latently infected and
do not participate in the GC response induced by MuHV-4 while
they are equally sensitive to infection in vitro. Moreover, our
ELISPOT data show that viral latency is not restricted to virus-
specific B cells, indicating that latency is established in B cells of
other specificities. This set of observations leads us to propose that
Figure 2. MuHV-4 latent infection is restricted to polyclonal HEL2 B cells. SWHEL mice were left untreated or infected for 14 days with YFP-
MuHV-4 virus at 104 PFU. Splenocytes were isolated and analyzed by FACS or sorted for plaque assay and limiting dilution PCR analysis. HEL+ and
HEL2 B cells were identified based on HEL-A647 binding and CD19 expression. (A) On top are representative FACS plots showing the percentage of
YFP+ cells in both populations at 0 and 14 dpi. Data are compiled in the graphics below showing percentage of YFP+ cells in HEL+ (grey circles) and
HEL2 (white circles) B cells at day 0 (n = 12) and 14 (n = 16) dpi. The bar represents the average percentage. (B) To detect presence of latent MuHV-4, a
plaque assay was performed on sorted HEL+ and HEL2 B cells 14 dpi (n = 8). # indicates that no plaques were detected in HEL+ B cells and based on
the average number of HEL+ B cells plated, we estimate the level of latent infection to be ,1 PFU/382000 in this population. The analysis of lysed
cells showed an absence of preformed viral particles in both populations. (C) Limiting dilution PCR was performed to detect viral genome in sorted
HEL+ and HEL2 B cells from day 14 infected SWHEL mice. Data are representative of two independent experiments in which splenocytes were pooled
before sorting (n = 3 & n = 2). The frequency of cells harboring MuHV-4 DNA is shown, # indicates signal below the assay’s limit of detection. We
evaluated the frequency of MuHV-4 DNA+ cells in HEL+ B cells to be #1/36770 and #1/102891 for the two experiments we performed. Error bars
indicate the 95% confidence interval. Purity of sorted cells was systematically above 90%.
doi:10.1371/journal.ppat.1004269.g002
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the establishment of latency is not a stochastic event and takes
place in a restricted population of polyclonal B cells. This model
implies that MuHV-4 does not overcome the stimulatory signals
provided by the BCR stimulation and the cognate CD4 help, but
manages to benefit from it in order to settle in long-lived memory
B cells.
To test if MuHV-4 could benefit from acute CD4-dependent B
cell responses, we stimulated a physiological number of adoptively
transferred HEL+ B cells in C57BL/6 mice with sheep red blood
cells (SRBC) conjugated to recombinant HEL [23]. We used an
adoptive transfer assay in order to avoid competition between
HEL+ B cells in SWHEL mice, in particular from being in too great
an excess over the available SRBC-specific CD4 help. Indeed,
SWHEL immunized with SRBC-HEL showed a poor GC response
(,1% of GC HEL+ B cells, Figure S3A) when compared to
C57BL/6 adoptively transferred with HEL+ B cells (,70% of GC
HEL+ B cells, Figure S3B). We controlled that SRBC-HEL could
not induce an endogenous HEL-specific B cell response in
C57BL/6 mice by co-transferring SRBC-HEL with or without
HEL+ B cells and showed that transferred HEL+ B cells were
required for the emergence of HEL+ GC B cells (Figure S3B).
As schematized in Figure 9A, we transferred HEL+ B cells 24 h
before infection and immunized the infected mice with SRBC+/2
HEL at 0, 4, 7 or 10 dpi. We decided to test different time of
immunization, as it is currently unknown when the virus/B cell
encounter happens and whether it infects naı̈ve or activated B cells
in vivo. At 14 dpi, we monitored the GC differentiation and
percentage of infection in HEL+ and HEL2 B cells (Figure 9B).
Immunization with SRBC-HEL at either of the time point tested
triggered the GC differentiation of HEL+ B cells when compared
to mice immunized with SRBC alone (Figure 9B, top left) while it
did not affect the GC phenotype of HEL2 B cells (Figure 9B,
bottom left). The magnitude of the GC response observed in
HEL+ B cells was different between the time of immunization,
certainly due to a mixed influence of the GC dynamic and survival
of the transferred cells. While we could detect for the first time a
HEL+ GC response in the context of MuHV-4 infection, these
cells remained YFP2 (Figure 9B, top right), YFP+ cells being
restricted to the HEL2 population (Figure 9B, bottom right), in
which frequency of infection was not affected by SRBC-HEL
immunization. We verified that adoptively transferred B cells
could get latently infected by transferring WT CD45.1+ spleno-
cytes into WT CD45.2+ recipient mice and showed that frequency
of infection and GC differentiation was equivalent between donor
and recipient cells (Figure S4).
These data support the fact that HEL+ GC B cells are resistant
to MuHV-4 latency and that MuHV-4 does not benefit from acute
B cell responses to establish latency in non-virus-specific B cells,
likely relying on other mechanisms yet to be identified.
Discussion
In this study, we attempted at better understanding how c-
herpesviruses establish latency in B cells with a particular focus on
the role of the BCR specificity. By following HEL+ B cells in
MuHV-4 infected SWHEL mice, we were able to monitor the
behavior of non-virus specific B cells during the establishment of
MuHV-4 latency and showed that those cells were excluded from
the latently infected population.
Previous studies have established that MuHV-4 latency depends
on B cell activation and proliferation [33], but it is still not clear
whether MuHV-4 can drive such activation independently of
BCR specificity. When we compared the proliferation and CD69
expression of HEL+ and HEL2 B cells, we observed that both
populations behave in a similar manner, with proliferation in both
spleen and CLN and a transient CD69 upregulation in the CLN.
This confirms previous work that showed CD69 upregulation on B
cells exposed to MuHV-4 in vitro and a temporary B cell
proliferation in MHC-II-deficient I-Ab2/2 mice [7]. However,
HEL+ B cells did not participate to the long-term humoral
response, as they did not differentiate into GC or plasma cells. We
think we observed here two distinct waves of activatory signals.
The first wave triggering a non-specific activation of the global B
cell population, followed by a second wave that promotes the
differentiation into GC of a restricted pool of B cells. The
respective role of these two waves in the establishment of latency is
Figure 3. YFP+ HEL2 B cells differentiate into GC and plasma
cells. Splenocytes were isolated from SWHEL mice 14 dpi and analyzed
by FACS. Cells were gated on the HEL2 CD19+ population. On top is
shown a typical phenotype of YFP+ HEL2 B cells, monitoring GC (CD95+
GL-7+) and plasma cells (IgM2 CD138+). Data were compiled in the
graphics below; showing the percentage of GC cells (n = 14) and plasma
cells (n = 11) in YFP+ HEL2 B cells.
doi:10.1371/journal.ppat.1004269.g003
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not completely clear, but the first wave of activation is not
sufficient to allow the establishment of latency in B cells, as
supported by the fact that HEL+ B cells do not get latently
infected. While we do not identify the mechanism driving the first
wave of activation, it has been shown that both T cells and B cells
are responsible for the MuHV-4 driven splenomegaly [30],
suggesting that the first wave of activation is not due to factors
specific of the B cell response, and is probably cytokine mediated.
Concerning the second wave of activation, correlation analysis
performed on our dataset showed that frequency of YFP+ cells in
HEL2 B cells correlates positively with the magnitude of the GC
response (Figure 10). This is in accordance with recent observa-
tions by Collins et al who observed a positive correlation between
the frequency of YFP+ cells and the frequency of follicular helper
T cells, an essential player of the GC response [10]. That said, the
fact that HEL+ B cells are sensitive to the virus in vitro but do not
get latently infected and are excluded from the GC reaction go
against a model where MuHV-4 could drive a stochastic
manipulation of the B cells and would instead rely on BCR
specificity.
One previous study looked at the influence of MuHV-4 on non-
virus specific B cells by reconstituting mMT B cell 2/2 mice with
B cells from MD4 mice (designated HELMET mice [34]). In
MuHV-4 infected HELMET, HEL+ B cells expressed CD69 and
proliferated but contrary to our results, MuHV-4 latency was
detected in HEL+ B cells by PCR. The absence of competition in
HELMET mice, where B cells are all HEL-specific could account
for these discrepancies. Indeed, in SWHEL mice, HEL
+ B cells
coexist with a majority of polyclonal B cells. Our in vitro infection
by co-culture assay supports the fact that HEL+ B cells are sensitive
to MuHV-4, suggesting that a selection mechanism might occur in
vivo, leading to the disappearance of these infected cells. In
HELMET mice, the absence of competition could allow for the
survival of latently infected HEL+ B cells. This role for competition
Figure 4. HEL+ and HEL2 B cells are both infected by MuHV-4 in vitro. In vitro infection by co-culture assay was performed as described in
the material and methods. Briefly, freshly isolated SWHEL splenocytes were exposed to free viruses or co-culture with BHK-21 or RAW-264 cells
previously infected with EF1a-eGFP+ or EF1a-eGFP+-gp1502 MuHV-4. GFP expression in HEL+ and HEL2 B cells was monitored by FACS after 48 h of
co-culture. Representative FACS plots are shown on top, compiled data representing average percentage and standard deviation are shown below.
Splenocytes were identified based on FSC SSC parameters, excluding BHK-21 and RAW-264. Cells were then gated on CD19+ CD11b2 and GFP
expression was monitored in HEL+ and HEL2 B cell. Data were obtained from two independent experiments with two splenocytes suspensions in
each.
doi:10.1371/journal.ppat.1004269.g004
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is supported by the work of Kim et al [35] who studied how
latency evolved in mice containing CD40+ and CD402 B cells.
Although the two populations got latently infected, latency was
ultimately lost in CD402 B cells and GC differentiation was
restricted to CD40+ B cells.
To explore whether the presence of CD4 T cell dependent
antigens could be involved in the selection of latently infected cells,
we triggered an endogenous anti-HEL response concomitantly
with MuHV-4 infection. Although we were able to induce the
emergence of HEL+ GC B cells, these cells remained refractory to
latent infection. These data support that, at least in our
experimental setting, MuHV-4 cannot hitchhike an acute humoral
response to gain access to GC B cells and might instead benefit
from other antigen/BCR interactions. In humans, it is estimated
that up to 20% of a normal B cell repertoire is made of self-
reactive B cells that need to be constantly kept under control
[36,37]. One of the tolerance mechanism is the induction of a
functional unresponsive state known as anergy, which requires
endogenous BCR signaling [38,39]. The high prevalence of self-
reactive B cells offers a good opportunity for c-herpesviruses to
manipulate these processes in order to retrieve B cells from their
anergic state and promote polyclonal B cells activation in an
antigen-dependent manner. Supporting this point, recent studies
performed in humans [40] and mice [41,42] have shown that c-
herpesviruses are found in self-reactive B cells. Two studies have
explored MuHV-4 impact on anergic B cells [42,43], but it is still
not clear how MuHV-4 can modulate this processes.
SWHEL6ML5 mice [21], in which HEL
+ B cells are anergic due
to the presence of soluble HEL, could be an alternative model to
study the influence of the virus on competent anergic B cells.
Further work will be required to elucidate how MuHV-4
promotes GC B cells differentiation independently of their infection
status, and how this event is linked to the establishment of latently
infected B cells in memory B cells. c-herpesviruses are known to be
Figure 5. Proliferation and transient activation of total B cells. Spleens and CLN from YFP-MuHV-4 infected SWHEL mice were harvested at 0,
7, 14 and 21 dpi and cells were stained with CD69 PE, CD19 APC-Cy7 and HEL-A647. (A) Live cells were enumerated, and the number of HEL+ and
HEL2 B cells was established based on their frequency obtained from the FACS data. (B) Representative FACS histograms showing CD69 expression
on HEL+ (grey curves) and HEL2 (white curves) B cells isolated from CLN and spleen at the different time points are shown. CD69 was monitored by
measuring the Geo MFI and compiled values are shown in the graphic below. (C) On the same samples, the frequency of CD69high cells was
evaluated. Representative FACS plots are shown and compiled percentages are presented in the graphic below. These data were obtained from two
independent experiments, with a total 5 to 6 mice per time point. In the graphics, mean values are reported and error bars represent the standard
deviation.
doi:10.1371/journal.ppat.1004269.g005
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mildly pathogenic in immune-competent hosts and it has been
shown that MuHV-4 latent infection does not induce autoimmune
disorders and actually confers protection in lupus-prone animals
[41]. This highlights the fact that the interrelationship between
MuHV-4 and B cells is complex and that co-evolution between c-
herpesviruses and their host as allowed for the emergence of subtle
mechanisms that promote B cell activation but limits associated
immune disorders in order to establish life-long latency.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of the Portuguese official Veterinary Director-
ate, which complies with the Portuguese Law (Portaria 1005/92).
The Portuguese Experiments on Animal Act strictly comply with
the European Guideline 86/609/EEC and follow the FELASA
(Federation of European Laboratory Animal Science Associations)
guidelines and recommendations concerning laboratory animal
welfare. All animal experiments were approved by the Portuguese
official veterinary department for welfare licensing under the
protocol number AEC_2010_017_PS_Rdt_General and the IMM
Animal Ethics Committee.
Mice
SWHEL mice [21] were obtained from Dr Antonio Freitas,
Institut Pasteur, Paris, in accordance with Dr Robert Brink,
Garvan Institute, Melbourne. To screen for expression of the
VH10tar heavy chain and the Vk10-k light chain genotyping was
performed on DNA isolated from mouse-tails using DirectPCR
solution (Viagen). Mice heterozygous for both genes were used for
experiments. HEL+ B cells were identified by FACS and confocal
microscopy (see details below) by direct labeling with recombinant
HEL (Sigma-Aldrich) conjugated with Alexa 647 (noted HEL-
A647). This conjugation was made with the Alexa Fluor Antibody
Labeling Kit (Invitrogen) following manufacturer instructions. A
Bio-Gel P-6 (Biorad) loaded column was used to separate HEL-
A647 conjugates from free dye. C57BL/6, CD45.1 and CD45.2
mice and were purchased from Charles Rivers Laboratories. Mice
were between 7 and 15 weeks old at time of infection and were
sacrificed by CO2 inhalation or cervical dislocation.
Viruses
The YFP expressing MuHV-4 [4] was obtained from Dr
Samuel Speck, Emory Vaccine Center, Atlanta. EF1a-eGFP+
MuHV-4 and EF1a-eGFP+-gp1502 MuHV-4 [29] were obtained
Figure 6. GC and plasma cell differentiation are restricted to the HEL2 B cells. Splenocytes were purified from SWHEL mice at 0 and 14 dpi
and analyzed by FACS. Cells were gated on (A) HEL+ or (B) HEL2 B cells for phenotype analysis, monitoring the frequency of GC (CD95+ GL-7+) and
plasma cells (IgM2 CD138+). Top parts of the figures show representative FACS plots, bottom parts are the compilation of data obtained from
different SWHEL mice (GC: day 0 n = 12; day 14 n = 16/Plasma cells: day 0 n = 10; day 14 n = 13). (C) Germinal center cells in C57BL/6 B cells and HEL
2 B
cells harbor an equivalent frequency of YFP+ cells. Frequency of YFP+ cells in GC cells was evaluated 14 dpi by gating on the CD95+ GL-7+ population
from total B cells of C57BL/6 mice (left dot plot and diamonds, n = 12) or from HEL2 B cells of SWHEL mice (right dot plot and circles, n = 16). The bar
represents the average percentage.
doi:10.1371/journal.ppat.1004269.g006
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from Philip Stevenson, University of Cambridge, Cambridge.
Viral stocks were prepared by infecting BHK-21 cells and titrated
by plaque assay using previously published procedures [44,45].
For infections, mice were anaesthetized with isoflurane and
inoculated intranasally with 104 pfu of YFP-MuHV-4 under
20 ml of PBS.
IgGs secreting cells ELISPOT assay
ELISPOT assay to enumerate MuHV-4 specific B cells was
adapted from [8]. Briefly, purified MuHV-4 were disrupted for
10 min in PBS+0.05% Triton X-100 and plated at 56106 PFU/
well in 96-well MultiScreen HA mixed cellulose filter plates
(Millipore, Billerica, MA). Plates were incubated overnight at 4uC,
washed with PBS and blocked for 1 h at 37uC with complete
medium (RPMI-1640+10% heat inactivated FBS, 2 mM
glutamine, 100 U/ml penicillin and streptomycin and 1 mM
sodium pyruvate). Latently infected (CD19+ YFP+) and non-
infected (CD19+ YFP2) B cells were sorted from spleens on a
FACS Aria (BD Biosciences). Serial four-fold dilutions of sorted
cells were prepared in complete medium and added under 100 ul/
well in four replicate wells per cell amount. Cells were incubated
overnight at 37uC in a humid 5% CO2 incubator. Plates were
washed with PBS and incubated for 2 h at room-temperature with
Alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG (H+
L) antibodies (Southern Biotech) diluted 1/500 in PBS+0.5% FBS.
After thorough washes spots were revealed at room temperature
with 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma) in
diethanolamine buffer. Upon optimal spot development plates
were washed and dried. Blue spots representing single antibody-
secreting cells (ASC) were counted under an Olympus SZ51
Figure 7. HEL+ B cells are excluded from the GC. Spleens were isolated from (A) day 0 (n = 2) and (B) day 14 (n = 4) infected SWHEL mice for
microscopy analysis. Spleens were treated as indicated in the material and methods, and stained with an anti-GFP, anti-GL-7, HEL and nuclei dye
Hoechst. Separate channels are shown as thumbnails, in the merge image below nuclei were excluded for clarity. Follicles (Fo) were localized based
on Hoechst signal, showing delimited clusters of nuclei. GCs were identified as clusters of GL-7+ cells. Spleen sections were thoroughly analyzed and
images shown are typical organization of splenic follicles of SWHEL mice at 0 and 14 dpi. At 14 dpi, infected cells were mainly localized within the GC,
from which HEL+ B cells were systematically excluded. Scale bars represent 100 mm.
doi:10.1371/journal.ppat.1004269.g007
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Figure 8. SWHEL mice mount a long-lasting anti-MuHV-4 antibody response. SWHEL mice were inoculated intranasally with PBS (n = 2) or
MuHV-4 (n = 6). At indicated time points, mice were bled and sera were analyzed by ELISA to monitor levels of circulating anti-MuHV-4 and anti-HEL
IgG1 (red triangles), IgG2a (blue squares) and IgG2b (green circles). For MuHV-4 infected mice, 3 independent experiments with 2 mice in each were
analyzed. As no standard were available to quantify these antibodies, samples of different time points from identical mice were run together to be
able to compare the absorbance at 405 nm.
doi:10.1371/journal.ppat.1004269.g008
Figure 9. Activated HEL+ B cells remain refractory to MuHV-4 infection. (A) Experimental design: Bulk SWHEL splenocytes containing 10
4
HEL+ B cells were transferred in C57BL/6 mice 24 h prior YFP-MuHV-4 infection. Recipient mice were challenged intravenously by a single
immunization with 2.108 SRBC or SRBC-HEL performed at 0, 4, 7 or 10 dpi. At 14 dpi, spleens were collected and analyzed by FACS. As shown in the
representative FACS plots, transferred HEL+ were identified with HEL-A647 staining while transferred HEL2 B cells could not be discriminated from
endogenous B cells. On both HEL+ and HEL2 (transferred+endogenous) B cells, GC differentiation and percentage of infection was determined using
GL-7/CD95 and YFP expression respectively. (B) For each time of immunization, frequency of GC B cells and YFP+ B cells were compared between
SRBC and SRBC-HEL immunized mice in both HEL+ (top panel) and HEL2 B cells (bottom panel). Each dot represents an individual mouse and bars
represent the average percentages. The data were obtained from 4 to 6 mice per experimental group.
doi:10.1371/journal.ppat.1004269.g009
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microscope. Total number of ASC were determined as described
above except that plates were coated with 0.5 mg/well of a goat
anti-mouse k antibodies (Southern Biotech) diluted in PBS.
In vitro infection by co-culture assay
In vitro infection by co-culture assay was adapted from [29].
24 h prior co-culture, 3.105 RAW-264 and BHK-21 cells were
seeded in 24-well plate. After cell adhesion (4–6 h), media was
removed and cell infected overnight with indicated MuHV-4 at
9.105 pfu per condition. The next day, spleens were harvested and
single cell suspensions were prepared by spleen disruption,
filtration on 100 mm cell strainer and red blood cells removal by
centrifugation on ficoll gradient (Biowest). Splenocytes were
washed and added to cells at 106/well. As a negative control,
splenocytes were exposed to free viruses. In order to have enough
cells to work with, spleens from two SWHEL mice were pooled. For
each experiments, two suspensions were analysed in parallel. After
48 h of co-culture, cells were harvested and stained with CD11b
(to exclude RAW-264 cells), CD19 and HEL. Infection of RAW-
264 was systematically evaluated 24 h post infection by monitoring
GFP expression in cells not co-cultured with splenocytes (data not
shown).
Flow cytometry
Single cell suspensions were prepared from spleens. Red blood
cells were lysed in hypotonic NH4Cl and stainings were performed
at 4uC in PBS+4% FCS and 1 mM EDTA. Briefly, cells were
blocked by 10 min incubation with FcBlock (anti-CD16/32,
2.4G2, BD bioscience), washed, and stained for 20 min. For
biotinilated antibodies, extra 20 min incubation with streptavidin
was performed. MuHV-4 infected cells were monitored based on
their endogenous YFP expression. The following antibodies were
used: anti-CD69 PE (H1.2F3), anti-CD95 PE (Jo2), anti-CD19
APC-Cy7 or APC-H7 (1D3), anti-IgM PE (R6-60.2), anti-IgD
Biotin (11-26c.2a), CD11b PE or v450 (M1/70) (BD Biosciences);
CD45.2 Brilliant Violet 510 (104) (BioLegend); anti-CD45.1
PeCy7 (A20), and anti-GL-7 Biotin (Ebioscience). Streptavidin-
Cy5 (BD Biosciences) was used to reveal biotinilated antibodies.
HEL specific B cells were identified with the HEL-A647 conjugate
described above. Samples were acquired on a FACS Canto or on a
LSR Fortessa (BD Biosciences), using DIVA software (BD
Biosciences) for acquisition and Flowjo v.6.4.7 (Tree Star) for
analysis. Cells were gated on live cells based on FSC/SSC
parameters and cell doublets were excluded based on FSC-W
signal.
Immunofluorescence histology
Spleens were fixed overnight at 4uC in periodate-lysin-
paraformaldehyde (PLP) [46,47] and dehydrated by successive
2 h incubation in 10%, 20% and 30% sucrose solutions at 4uC.
Spleens were then embedded in OCT (Tissue Tek), frozen and
sectioned (40 mm). For immunofluorescence staining, sections
were encircled with a Fatpen and rehydrated 10 min in phosphate
buffer. All incubations were made in humid chamber, protected
from light. Sections were permeabilized for 1 h at room
temperature in 1% triton and blocked 1 h in 1% BSA+FcBlock
(anti-CD16/32, 2.4G2, BD bioscience). Stainings were performed
using the following reagents: anti-GFP Alexa 488 (Invitrogen),
anti-GL-7 Biotin (GL-7, Ebioscience), HEL-A647 (described
above) and Hoechst 33343 (Invitrogen). Streptavidin Alexa568
(Invitrogen) was used for biotinilated antibodies, incubated 1 h at
room temperature. Slides were washed, mounted in Fluoromount-
G (SouthernBiotech) and kept at 4uC. Images were acquired on a
LSM 510 META point scanning confocal microscopes (Zeiss) and
analyzed using LSM Image Browser (Zeiss) and Photoshop CS2
(Adobe).
Figure 10. The frequency of infection correlates with the magnitude of the germinal center response in HEL2 B cells. To study the
interrelationship between the GC response and the frequency of YFP+ cells, matched data obtained from SWHEL mice 14 dpi (n = 16) were plotted
against each other. For each SWHEL mouse, the Y-axis shows the frequency of YFP
+ cells in HEL2 B cells (data from Figure 2A) and the X-axis shows the
frequency of GC (data from Figure 6B). Rs was calculated using Spearman’s rank correlation coefficient.
doi:10.1371/journal.ppat.1004269.g010
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Cell sorting and in vitro reactivation assay
HEL+ B cells (CD19+, HEL+) and HEL2 B cells (CD19+,
HEL2) were sorted using a FACS Aria (BD Biosciences) and used
for in vitro reactivation assay to quantify latent infection. Serial
dilutions of freshly isolated cells were co-cultured with BHK-21 in
complete media supplemented with 50 mg/ml of Gentamycin
(Invitrogen). Lysing half of the sorted cells by a quick freeze/thaw
cycle before coculture allowed us to assess the presence of
preformed viral particles, indicative of lytic infection. After 5 days,
BHK-21 were fixed with 4% paraformaldehyde and stained with
toluidine blue for plaque counting. The number of plaques in each
sample was expressed as plaques forming unit (pfu)/107 cells.
Limiting dilution PCR analysis
The frequency of virus-genome-positive cells was determined
from pools of 2 to 3 spleens by limiting dilution combined with
real-time PCR as previously described [48]. Sorted HEL+ and
HEL2 B cells were serially two-fold diluted and eight replicates of
each dilution were analysed by real time PCR (Rotor Gene 6000,
Corbett Life Science). The primer/probe sets were specific for the
MuHV-4 M9 gene (59 primer: GCCACGGTGGCCCTCTA; 39
primer: CAGGCCTCCCTCCCTTTG; probe: 6-FAM-CTT-
CTGTTGATCTTCC–MGB). Samples were subjected to a
melting step of 95uC for 10 min followed by 40 cycles of 15 s at
95uC and 1 min at 60uC. Positive vs. negative reactions were
scored using the Rotor Gene 6000 software. Our data were
compatible with the single-hit Poisson model (SHPM) as tested by
modeling the limiting dilution data according to a generalized
linear log-log model fitting the SHPM and checking this model by
an appropriate slope test as described [3,49]. A regression plot of
input cell number against log fraction-negative samples was used
to estimate the frequency of cells with viral genomes. Estimation of
the cell subset frequency of MuHV-4 infection consisted of
computation by maximal-likelihood estimation as follows: let f be
the estimate of the cell frequency; the maximum likelihood of f is
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where log(L) is the natural logarithm of the likelihood function L
and Pi is given by Pi = exp(-f xi) according to the SHPM. The
variance of f was calculated as the negative reciprocal of the
second derivative of log(L), var(f) = 1/[d2 log(L)/df2]. The 95%
confidence interval (CI) for f was calculated as 95% CI
(f) = f61.96SE (f). Abbreviations are as follows: k = the number
of groups of replicate PCRs, numbered i = 1, 2, … k; ni = the
number of replicate reactions; ri = the number of observed
negative PCRs; and mi = the observed fraction of negatives
(mi = ri/ni).
Adoptive transfers and SRBC+/2HEL immunization
Freshly isolated bulk splenocytes from SWHEL mice containing
104 HEL+ B cells were transferred into C57BL/6 mice by
intravenous injection, as previously described [50]. Sheep red
blood cells (SRBC) were obtained from Miguel Fevereiro,
Laboratório Nacional de Investigação Veterinária, Lisbon.
Recombinant HEL was covalently conjugated to SRBC with 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (Sig-
ma-Aldrich) as described [25]. Conjugation was confirmed by
FACS by staining mock or HEL-conjugated SRBC with the
HyHEL10 (an anti-HEL IgG1 [21]) followed by an anti-IgG1 APC
(BD Biosciences). HEL-A647 was used to identify transferred
HEL+ B cells.
Anti-HEL and anti-MuHV-4 IgGs ELISA
To measure anti-HEL and anti-MuHV-4 antibody production,
sera were regularly collected by facial-vein bleeding. To measure
HEL-specific antibodies, maxisorp plates (Nunc) were coated with
60 ml of recombinant HEL (10 mg/ml) diluted in NPP buffer
(adapted from [21]). For MuHV-4 antibodies, plates were coated
with viral particles disrupted with 0,1% triton and diluted in NPP
buffer (adapted from [7]). Coated plates were incubated overnight
at 4uC and blocked for 1 h with 100 ml PBS+1% BSA. Sera were
diluted to 1/200 in PBS+0,1% BSA and 50 ml were incubated 2 h
at room temperature. IgG1, IgG2a and IgG2b subclasses were
measured using 50 ml of anti-mouse IgG1, IgG2a and IgG2b
conjugated to alkalyne-phosphatase (SouthernBiotech) diluted to
1/500 and incubated 1 h at room temperature. Bound antibodies
were revealed using 100 ml of 1 mg/ml P-Nitrophenyl Phosphate
(MP Biomedical) prepared in NPP buffer and incubated 40 min at
37uC. Absorbance was measured at 405 nm.
Statistics
p values were calculated using non-parametric Mann-Whitney
U test; ns indicates p.0.05, * indicates p#0,05, ** indicates p#
0,005, and *** indicates p#0,001.
Supporting Information
Figure S1 B-2 lineage represents the majority of latently
infected B cells. C57BL/6 (n = 5) were infected with YFP-
MuHV-4 and spleens were analyzed 14 dpi. Cells were stained
with CD19, CD5 and CD43 to identify B-2 (CD52 CD432), B-1a
(CD5+ CD43+) and B-1b (CD52 CD43+) B cells. (A) Represen-
tative FACS plots from YFP2 (left) and YFP+ (right) B cells are
shown. (B) Average population percentages obtained from the 5
mice are shown for the YFP2 (grey bars) and YFP+ (black bars) B
cells.
(TIF)
Figure S2 MuHV-4 is restricted to HEL2 B cells in both
LNs and spleen (complement to Figure 5). Spleens and
CLN from YFP-MuHV-4 infected SWHEL mice were harvested at
0, 7, 14 and 21 dpi and cells were stained with CD69 PE, CD19
APC-Cy7 and HEL-A647. Frequency of infected cells was
monitored in HEL+ (Left panel) and HEL2 B cells (right panel)
based on YFP expression. Representative FACS plots are shown
and compiled percentages are presented in the graphic below.
These data were obtained from two independent experiments,
with a total of 5 to 6 mice per time point. In the graphics, mean
values are reported and error bars represent the standard
deviation.
(TIF)
Figure S3 Poor GC response in SWHEL mice and
absence of endogenous HEL+ B cell activation in
C57BL/6 challenged with SRBC-HEL. (A) SWHEL mice
were immunized intravenously with 2.108 SRBC (n = 3) or 2.108
SRBC-HEL (n = 3). 7 days post-challenge splenocytes were
harvested and analyzed by FACS. Representative FACS plots
shows frequency of GC cells (CD95+ GL-7+) in HEL+ B cell from
mice challenged with SRBC or SRBC-HEL. (B) C57BL/6 were
immunized intravenously with 2.108 SRBC-HEL in presence
(n = 3) or absence (n = 3) of co-transferred 104 HEL+ B-cells. 7
days post-challenge splenocytes were harvested and analyzed by
FACS. Representative FACS plots shows the frequency of HEL+
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B-cells and their GC phenotype (CD95+ GL-7+) in each condition.
A HEL+ B cell population with a GC phenotype was only detected
when HEL+ B cells were co-transferred with SRBC-HEL,
indicating that SRBC-HEL alone induced an undetectable
HEL-specific response in C57BL/6.
(TIF)
Figure S4 Adoptively transferred B cells get latently
infected. 24 h prior MuHV-4 YFP infection, CD45.2 C57BL/6
recipient mice (n = 6) received intravenously 107 bulk splenocytes
freshly isolated from CD45.1 C57BL/6 donor mice. At 14 dpi,
spleens were isolated and cells stained with anti-CD19, CD95 and
GL-7 as well as with anti-CD45.1 and CD45.2 in order to
discriminate between donor (CD45.1+) and endogenous (CD45.2+)
B cells. MuHV-4 infection in CD45.1+ and CD45.2+ B cells was
evaluated by monitoring the frequency of YFP+ cells in each
population (top panel). GC phenotype was assessed by monitoring
CD95 and GL-7 expression on CD45.1+ and CD45.2+ B cells
(central panel) as well as on YFP+ B cells in each population
(bottom panel). For each panel, representative FACS plots and
compiled data are shown. Bars represent average percentages.
(TIF)
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